1st Counsel – Lifestyle
Author:
Outlook Therapeutics, Inc.
Outlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
April 22, 2026
Outlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
April 21, 2026
Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDA
April 7, 2026
Outlook Therapeutics Announces Closing of $5.0 Million Public Offering
March 25, 2026
Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering
March 24, 2026
Outlook Therapeutics Announces Proposed Public Offering
March 23, 2026
Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note
March 16, 2026
Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg)
March 5, 2026